Skip to Content

'
Lance C. Pagliaro

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Genitourinary (GU) Medical Oncology, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 1374
Houston, TX 77030
Room Number: CPB7.3458
Phone: 713-792-2830
Fax: 713-794-1446

Education & Training

Degree-Granting Education

1987 Albany Medical College, Albany, NY, MD, Medicine
1983 Amherst College, Amherst, MA, BA, Magna Cum Laude, Biology and Anthropology

Postgraduate Training

7/1992-6/1993 Clinical Fellowship, Hematology and Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
7/1990-6/1992 Clinical Fellowship, Hematology and Medical Oncology, The George Washington University Medical Center, Washington, DC
7/1988-6/1990 Clinical Residency, Internal Medicine, The George Washington University Medical Center, Washington, DC
7/1987-6/1988 Clinical Internship, Internal Medicine, The George Washington University Medical Center, Washington, DC

Board Certifications

1999 American Board of Medical Oncology
1994 American Board of Hematology
1990 American Board of Internal Medicine
1988 National Board of Medical Examiners

Experience/Service

Academic Appointments

Assistant Professor, Department of Genitourinary (GU) Medical Oncology, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX, 1995-2004
Faculty Associate, Clinical Investigation, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1993-1995
Junior Faculty Associate, Department of Medical Specialties, Division of Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX, 1992-1993

Institutional Committee Activities

Member, Executive Committee of the Medical Staff (ECMS), 9/2008-present
Member, Facilities Steering Committee, 9/2008-present
Chair-Elect, Faculty Senate, 9/2008-8/2009
Member, Executive Committee of the Faculty Senate, 2007-present
Senator, Faculty Senate, 2005-present
Member, Credentials Committee of the Medical Staff (CCMS), 2004-present
Member, Clinical and Translational Research Center Steering Committee, 2000-2004
Member, Office of Research Administration Scientific Advisory Group, 1999-present
Member, Research Funding Oversight Committee, 1999-present
Chair, Research Affairs Committee of the Faculty Senate, 1999-2009
Member, Executive Committee of the Faculty Senate, 1999-2003
Senator, Faculty Senate, 1995-2003
Member, Tenure Issues Committee of the Faculty Senate, 1995-2003
Member, Medical Records Subcommittee, 1995-2001

Honors and Awards

1995 Clinical Oncology Career Development Award, American Cancer Society
1985 Glenn H. Leak Memorial Summer Fellowship, American Cancer Society
1983 Bachelor of Arts magna cum laude, Amherst College
1982 Sidney Farber Award for Outstanding Achievement, Roswell Park Memorial Institute

Selected Publications

Peer-Reviewed Original Research Articles
1. Osai WE, Ng CS, Pagliaro LC. Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma. Anticancer Drugs 19(4):427-29, 4/2008. PMID: 18454053.
2. Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, Srivastava P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer 98(8):1336-41, 4/2008. PMID: 18362942.
3. Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE. Adaptive therapy for androgen-independent prostate cancer: A randomized selection trial of four regimens. J Natl Cancer Inst 99(21):1613-22, 10/2007. PMID: 17971530.
4. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 107:2254-61, 11/2006. PMID: 17029276.
5. Pagliaro LC, Perez CA, Tu SM, Daliani DD. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma. Urol Oncol 24:487-91, 11/2006. PMID: 17138128.
6. Mathew P, Logothetis CJ, Dieringer PY, Chen I, Pagliaro LC, Bekele BN, Zhou X, Daliani DD. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer 5:144-9, 9/2006. PMID: 17026803.
7. Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer 107(3):497-505, 8/2006. PMID: 16795067.
8. Rodney A, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC. Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer 106(10):2143-7, 5/2006. PMID: 16598751.
9. Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol 174(6):2186-90, 12/2005. PMID: 16280761.
10. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 23(31):7904-10, 11/2005. PMID: 16258090.
11. Leibovici D, Pagliaro L, Rosser CJ, Pisters LL. Salvage surgery for bulky local recurrence of prostate cancer following radical prostatectomy. J Urol 173(3):781-3, 3/2005. PMID: 15711269.
12. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22(11):2108-21, 6/2004. PMID: 15169797.
13. Pagliaro LC, Keyhani A, Liu B, Perrotte P, Wilson D, Dinney CP. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urol Oncol 21(6):456-62, 11/2003. PMID: 14693272.
14. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102(10):3829-36, 11/2003. PMID: 12881308.
15. Pearlman M, Jendiroba D, Pagliaro L, Keyhani A, Liu B, Freireich EJ. Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines. Leuk Res 27(7):617-26, 7/2003. PMID: 12681361.
16. Pagliaro LC, Keyhani A, Williams D, Woods D, Liu B, Perrotte P, Slaton JW, Merritt JA, Grossman HB, Dinney CP. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol 21(12):2247-53, 6/2003. PMID: 12805322.
17. Pagliaro LC, Millikan RE, Tu SM, Williams D, Daliani D, Papandreou CN, Logothetis CJ. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol 20(13):2965-70, 7/2002. PMID: 12089226.
18. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357(9253):336-41, 2/2001. PMID: 11210994.
19. Pagliaro L, Daliani D, Amato R, Tu SM, Jones D, Smith T, Logothetis C, Millikan R. A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer 89(3):615-8, 8/2000. PMID: 10931461.
20. Perrotte P, Wood M, Slaton JW, Wilson DR, Pagliaro L, Price RE, Dinney CP. Biosafety of in vivo adenovirus-p53 intravesical administration in mice. Urology 56(1):155-9, 7/2000. PMID: 10869658.
21. Wood M, Perrotte P, Onishi E, Harper ME, Dinney C, Pagliaro L, Wilson DR. Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther 6(4):367-72, 7/1999. PMID: 10419055.

Abstracts
1. Siefker-Radtke AO, Kamat AM, Williams DL Tannir NM, Tu S, Pagliaro LC, Dinney CP, Millikan RE. A Phase II Randomized 4-Regimen Selection Trial Incorporating Response for Sequential Chemotherapy in Metastatic, Unresectable Urothelial Cancer: Final Results from MD Anderson Cancer Center. 2009 Genitourinary Cancers Symposium Proceedings(238):198, 2/2009.
2. Tannir NM, Zurita AJ, Heymach JV, Tran HT, Pagliaro LC, Corn P, Aparicio AM, Ashe R, Wright JJ, Jonasch E. A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis. 2008 ASCO Proc 26(15S):#5093, 5/2008.
3. Pagliaro LC, Osai W, Tamboli P, Vakar-Lopez F, Pettaway CA. Epidermal growth factor receptor expression in and targeted therapy for metastatic squamous cell carcinoma of the penis. J Clin Oncol 25(18S) (#14045), 2007.
4. Pagliaro LC, Williams D, Daliani D, Tu SM, Kincaid M, Heller L, Pettaway C. Neoadjuvant Paclitaxel (P), Ifosfamide (I), and Cisplatin (C) chemotherapy prior to inguinal/pelvic lymphadenectomy for stage Tany, N2-3, M0 squamous carcinoma (SCC) of the penis. J Urol 174 (suppl):195:A602, 2006.
5. Rodney AJ, Siefker-Radtke A, Tannir NM, Swisher S, Walsh G, Millikan RE, Pagliaro LC. Treatment outcomes of patients (pts) with primary mediastinal germ cell tumors (PMGCT): The M. D. Anderson Cancer Center (MDACC) experience. J Clin Oncol 24(18S):640s (#A14538), 2006.
6. Jonasch E, Tu SM, Tannir NM, Pagliaro LC, Mathew P, Siefker-Radtke AO, Wen S, General R, Lin SH, Logothetis CJ. Bone-targeted therapy consisting of zoledronate, thalidomide, and gamma interferon in renal cell carcinoma: a phase II study. J Clin Oncol 23(444s):A4769 (#A4769), 2005.
7. Tu SM, Kim J, Pagliaro C, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Long-term effects of stronium-89 combined with chemotherapy in patients with androgen-independent prostate cancer and bone metastases. J Clin Oncol 23(16S):420s (#A4671), 2005.
8. Rodney AJ, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC. Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer wtih prior taxane exposure. J Clin Oncol 23(16S):440s (#A4750), 2005.
9. Tannir NM, Wang X, Ng CS, Poulter VA, Mathew P, Siefker-Radtke AO, Jonasch E, Pagliaro LC, Cohen L, Millikan RE. A randomized phase III trial of low dose versus intermediate dose interferon alfa (IFN) as front-line therapy in advanced progressive renal cell cancer (RCC). J Clin Oncol 22(14S) (#4607), 7/2004.
10. Siefker-Radtke AO, Thall PF, Tannir NM, Tu SM, Pagliaro LC, Williams DL, Millikan RE. Randomized, adaptive phase II selection trial of four chemotherapy regimens in androgen independent prostate cancer. J Clin Oncol 22(14S):397s (#A4561), 2004.
11. Millikan RE, Thall P, Pagliaro L, Williams D, Brown M, Logothetis C. Randomized phase III trial of low dose versus intermediate dose interferon alfa as front-line therapy in advanced progressive renal cell cancer. J Clin Oncol 22(14S):408s (#4607), 2004.

Grant & Contract Support

Title: p53 Gene Therapy for Locally Advanced Bladder Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 1/1/1999 - 1/1/2001
 
Title: Clinical Study of p53 Gene Therapy in Bladder Cancer
Funding Source: PRS Research Committee
Role: Principal Investigator
Duration: 2/1/1998 - 3/1/1999
 
Title: Culture of Fresh Blast Cells from Patients with AML: A Model for Systemic Malignancy
Funding Source: American Cancer Society (ACS)
Role: Principal Investigator
Duration: 7/1/1995 - 6/1/1998
 
Title: A Risk-adapted Strategy of the Use of Dose-dense Chemotherapy in Patients with Poor-prognosis Disseminated Non-seminomatous Germ Cell Tumors: A Phase III Trial
Funding Source: Sanofi-Aventis
Role: Principal Investigator

Last updated: 8/28/2009